Abdel-Fattah, M.M.; Hassanein, E.H.M.; Sayed, A.M.; Alsufyani, S.E.; El-Sheikh, A.A.K.; Arab, H.H.; Mohamed, W.R.
Targeting SIRT1/FoxO3a/Nrf2 and PI3K/AKT Pathways with Rebamipide Attenuates Acetic Acid-Induced Colitis in Rats. Pharmaceuticals 2023, 16, 533.
https://doi.org/10.3390/ph16040533
AMA Style
Abdel-Fattah MM, Hassanein EHM, Sayed AM, Alsufyani SE, El-Sheikh AAK, Arab HH, Mohamed WR.
Targeting SIRT1/FoxO3a/Nrf2 and PI3K/AKT Pathways with Rebamipide Attenuates Acetic Acid-Induced Colitis in Rats. Pharmaceuticals. 2023; 16(4):533.
https://doi.org/10.3390/ph16040533
Chicago/Turabian Style
Abdel-Fattah, Maha M., Emad H. M. Hassanein, Ahmed M. Sayed, Shuruq E. Alsufyani, Azza A. K. El-Sheikh, Hany H. Arab, and Wafaa R. Mohamed.
2023. "Targeting SIRT1/FoxO3a/Nrf2 and PI3K/AKT Pathways with Rebamipide Attenuates Acetic Acid-Induced Colitis in Rats" Pharmaceuticals 16, no. 4: 533.
https://doi.org/10.3390/ph16040533
APA Style
Abdel-Fattah, M. M., Hassanein, E. H. M., Sayed, A. M., Alsufyani, S. E., El-Sheikh, A. A. K., Arab, H. H., & Mohamed, W. R.
(2023). Targeting SIRT1/FoxO3a/Nrf2 and PI3K/AKT Pathways with Rebamipide Attenuates Acetic Acid-Induced Colitis in Rats. Pharmaceuticals, 16(4), 533.
https://doi.org/10.3390/ph16040533